Aurélie Pelissier1, Claire Bonneau2, Elisabeth Chéreau3, Thibault DE LA Motte Rouge4, Virginie Fourchotte5, Emile Daraï6, Roman Rouzier7. 1. Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Department of Gynecology-Obstetrics, University Reims Hospital, Reims, France a.komorek@gmail.com. 2. Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Department of Gynecological Surgery, Tenon Hospital, Paris, France. 3. Department of Surgical Oncology, Institut Paoli-Calmettes, Marseille, France. 4. Department of Oncology, Centre René Huguenin, Institut Curie, Saint Cloud, France. 5. Department of Breast and Gynecological Surgery, Institut Curie, Paris, France. 6. Department of Gynecological Surgery, Tenon Hospital, Paris, France. 7. Department of Breast and Gynecological Surgery, Institut Curie, Paris, France Versailles-St-Quentin-en-Yvelines University, EA 7285: Risques Cliniques et Sécurité en Santé des Femmes et en Santé Périnatale, Montigny-Le-Bretonneux, France.
Abstract
AIM: Our objective was to evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum. MATERIALS AND METHODS: Patients diagnosed between 2002 and 2009, and treated with NAC and interval debulking surgery, were included in the study. RESULTS: One hundred and forty-two patients met the study inclusion criteria. Fifty-four patients (38%) were platinum-sensitive (PFI >12 months). A CA125 level after the 3rd NAC cycle <35 UI/ml was significantly associated with improved overall survival (OS) and relapse-free survival (RFS). In the multivariate model, patients with a CA125 level after the 3rd NAC cycle >35 UI/ml were 3.8-times more at risk for PFI <12 months (95% CI=1.7-8.5, p<0.001). CONCLUSION: A CA125 level after the 3rd NAC <35 UI/ml is an independent predictor for tumor platinum-sensitivity. Copyright
AIM: Our objective was to evaluate the kinetic parameters of serum CA125 during neoadjuvant platinum-based chemotherapy (NAC), in patients with epithelial ovarian cancer, in order to identify a surrogate marker of sensitivity to platinum. MATERIALS AND METHODS:Patients diagnosed between 2002 and 2009, and treated with NAC and interval debulking surgery, were included in the study. RESULTS: One hundred and forty-two patients met the study inclusion criteria. Fifty-four patients (38%) were platinum-sensitive (PFI >12 months). A CA125 level after the 3rd NAC cycle <35 UI/ml was significantly associated with improved overall survival (OS) and relapse-free survival (RFS). In the multivariate model, patients with a CA125 level after the 3rd NAC cycle >35 UI/ml were 3.8-times more at risk for PFI <12 months (95% CI=1.7-8.5, p<0.001). CONCLUSION: A CA125 level after the 3rd NAC <35 UI/ml is an independent predictor for tumorplatinum-sensitivity. Copyright
Authors: Martin Widschwendter; Michal Zikan; Benjamin Wahl; Harri Lempiäinen; Tobias Paprotka; Iona Evans; Allison Jones; Shohreh Ghazali; Daniel Reisel; Johannes Eichner; Tamas Rujan; Zhen Yang; Andrew E Teschendorff; Andy Ryan; David Cibula; Usha Menon; Timo Wittenberger Journal: Genome Med Date: 2017-12-22 Impact factor: 11.117
Authors: Yong Jae Lee; In Ha Lee; Yun-Ji Kim; Young Shin Chung; Jung-Yun Lee; Eun Ji Nam; Sunghoon Kim; Sang Wun Kim; Young Tae Kim Journal: PLoS One Date: 2018-09-06 Impact factor: 3.240